Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
Novartis (NOVN.S) breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly (LLY.N).
Comments